EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Treatments affecting splenic function as a risk factor for valvular heart disease in Childhood Cancer Survivors: A DCCSS‐LATER study

Bente M Houtman iD, Iris Walraven, Livia Kapusta, Arco J Teske, Eline van Dulmen-den Broeder, Wim J E Tissing, Marry M van den Heuvel-Eibrink, A B Birgitta Versluys, Dorine Bresters, Margriet van der Heiden-van der Loo, Cécile Ronckers, Wouter E M Kok und 7 weitere

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.31251 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Bente M Houtman und 18 weiteren Autor:innen. Beteiligte Einrichtung: Radboudumc Center of Expertise for Cancer Survivorship, Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Cancer Survivors, Splenectomy, Heart Valve Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Union's Seventh Framework Programme for research, technological development, and demonstration, KWF Kankerbestrijding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Splenectomy might be a risk factor for valvular heart disease (VHD) in adult Hodgkin lymphoma survivors. As this risk is still unclear for childhood cancer survivors (CCS), the aim of this study is to evaluate the association between treatments affecting splenic function (splenectomy and radiotherapy involving the spleen) and VHD in CCS.

Methods

CCS were enrolled from the DCCSS‐LATER cohort, consisting of 6,165 five‐year CCS diagnosed between 1963 and 2002. Symptomatic VHD, defined as symptoms combined with a diagnostic test indicating VHD, was assessed from questionnaires and validated using medical records. Differences in the cumulative incidence of VHD between CCS who received treatments affecting splenic function and CCS who did not were assessed using the Gray test. Risk factors were analyzed in a multivariable Cox proportional hazards model.

Results

The study population consisted of 5,286 CCS, with a median follow‐up of 22 years (5‐50 years), of whom 59 (1.1%) had a splenectomy and 489 (9.2%) radiotherapy involving the spleen. VHD was present in 21 CCS (0.4%). The cumulative incidence of VHD at the age of 40 years was significantly higher in CCS who received treatments affecting splenic function (2.7%, 95% confidence interval (CI) 0.4%‐4.9%) compared with CCS without (0.4%, 95% CI 0.1%‐0.7%) (Gray's test, p = 0.003). Splenectomy was significantly associated with VHD in a multivariable analysis (hazard ratio 8.6, 95% CI 3.1‐24.1). Conclusions and implications Splenectomy was associated with VHD. Future research is needed to determine if CCS who had a splenectomy as part of cancer treatment might benefit from screening for VHD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer SurvivorsSplenectomyHeart Valve DiseasesHumansMaleFemaleRisk FactorsAdultAdolescentChildFollow-Up StudiesChild, PreschoolYoung AdultSpleenMiddle AgedIncidenceHodgkin DiseasePrognosis

Stichwörter der Autor:innen

Childhood cancer survivorsheart valve diseaseslate effectsspleensplenectomy

Autor:innen und Institutionen

  • Radboudumc Center of Expertise for Cancer Survivorship, Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Pediatric Cardiology, Amalia Children's Hospital, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Pediatrics, Pediatric Cardiology Unit, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands.

ORCID-Profile: Bente M Houtman, E A M Lieke Feijen

Förderung

  • European Union's Seventh Framework Programme for research, technological development, and demonstration
  • KWF Kankerbestrijding

Zitieren

APA

Houtman, B. M., Walraven, I., Kapusta, L., Teske, A. J., van Dulmen-den Broeder, E., Tissing, W. J. E., van den Heuvel-Eibrink, M. M., Versluys, A. B. B., Bresters, D., van der Heiden-van der Loo, M., Ronckers, C., Kok, W. E. M., van der Pal, H. J. H., Pluijm, S. M. F., Janssens, G. O., Blijlevens, N. M. A., Kremer, L. C. M., Loonen, J. J., & Feijen, E. A. M. L. (2024). Treatments affecting splenic function as a risk factor for valvular heart disease in Childhood Cancer Survivors: A DCCSS‐LATER study. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31251

Vancouver

Houtman BM, Walraven I, Kapusta L, Teske AJ, van Dulmen-den Broeder E, Tissing WJE, et al. Treatments affecting splenic function as a risk factor for valvular heart disease in Childhood Cancer Survivors: A DCCSS‐LATER study. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31251

BibTeX
@article{Houtman2024,
  author = {Houtman, Bente M and Walraven, Iris and Kapusta, Livia and Teske, Arco J and van Dulmen-den Broeder, Eline and Tissing, Wim J E and van den Heuvel-Eibrink, Marry M and Versluys, A B Birgitta and Bresters, Dorine and van der Heiden-van der Loo, Margriet and Ronckers, Cécile and Kok, Wouter E M and van der Pal, Helena J H and Pluijm, Saskia M F and Janssens, Geert O and Blijlevens, Nicole M A and Kremer, Leontien C M and Loonen, Jacqueline J and Feijen, E A M Lieke},
  title = {Treatments affecting splenic function as a risk factor for valvular heart disease in Childhood Cancer Survivors: A DCCSS‐LATER study},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.31251}
}
Kostenlos starten →